Innate Pharma SA stock analysis
Innate Pharma SA (0EVI) Share Price & Analysis
0EVI Stock Chart & Stats
- Day’s Range
- EUR 1.26 - EUR 1.34
- 52-Week Range
- EUR 1.04 - EUR 2.33
- Previous Close
- EUR 1.32
- Volume
- N/A
- Average Volume (3M)
- 10.75K
- Market Cap
- EUR 148.11M
- Enterprise Value
- EUR 161.31M
- Total Cash (Recent Filing)
- EUR 10.90M
- Total Debt (Recent Filing)
- EUR 20.21M
- Price to Earnings (P/E)
- ―
- Beta
- 0.58
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- -0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partnership Economics
The Sobi partnership provides external validation for lacutamab while adding upfront cash, milestone potential and future royalties. It also places development alongside a larger pharmaceutical partner, improving commercialization resources and reducing reliance on Innate’s standalone capabilities.
Extended Cash Runway
An extended runway gives Innate time to advance key clinical programs and reach important data milestones before needing additional capital. This improves near-term execution flexibility, although the benefit depends on spending discipline and the timing of future development decisions.
Clinical And Regulatory Pipeline
Multiple regulatory designations support lacutamab’s development path by recognizing serious disease need and potentially enabling closer regulatory interaction or expedited review. Combined with Phase 3 development, they strengthen the program’s strategic position over the medium term.
Bears Say
Severe Revenue Deterioration
The sharp revenue decline and widening operating losses indicate that Innate has not yet established a stable commercial earnings base. Persistent weak profitability increases dependence on partnerships, financing and successful clinical development to support ongoing operations.
Fragile Capital Structure
Negative equity and a shrinking asset base reduce the financial cushion available to absorb continued losses or unexpected development costs. The weaker capital structure can constrain strategic flexibility and increase the importance of securing external funding on acceptable terms.
Ongoing Cash Burn And Funding Needs
Consistently negative operating and free cash flow shows that reported losses are translating into real cash consumption. Although current funding supports initial IPH4.5k work, broader expansion could require more capital, creating dilution or financing risk.
Innate Pharma SA News
0EVI FAQ
What was Innate Pharma SA’s price range in the past 12 months?
What is Innate Pharma SA’s market cap?
When is Innate Pharma SA’s upcoming earnings report date?
How were Innate Pharma SA’s earnings last quarter?
Is Innate Pharma SA overvalued?
Does Innate Pharma SA pay dividends?
What is Innate Pharma SA’s EPS estimate?
How many shares outstanding does Innate Pharma SA have?
What happened to Innate Pharma SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Innate Pharma SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Innate Pharma SA
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan E. Dickinson
- Employees
- 120
- Website
- www.innate-pharma.com
- Address
- 117, Avenue de Luminy, Marseille, PAC, 13009, FR
Innate Pharma SA (0EVI) Earnings & Revenues
0EVI Company Deck
0EVI Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with significant progress across the portfolio, including the closing of the Sobi partnership, initiation of lacutamab's Phase 3 study, completion of IPH4.5 thousand dose escalation, completion of PACIFIC-9 enrollment, positive preliminary IPH4.5 thousand activity and safety observations, and a projected cash runway through the end of the first quarter of 2028. The main constraints were that IPH4.5 thousand data remain early, enrollment in its non-small cell lung cancer cohort was somewhat lower, and broader development could require additional funding.
View all GB:0EVI earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 1 | 0 | 11 |
